On October 28, 2021 Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, reported that the Company has scheduled the release of its third quarter 2021 financial results on Thursday, November 4, 2021 (Press release, Sangamo Therapeutics, OCT 28, 2021, View Source [SID1234592196]). The press release will be followed by a conference call at 9:15 a.m. ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review its financial results and provide business and clinical updates.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The conference call dial-in numbers are (877) 377-7553 for domestic callers and (678) 894-3968 for international callers. The conference ID number for the call is 5178059. Participants may access the live webcast via a link on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. A conference call replay will be available for one week following the conference call. The conference call replay numbers for domestic and international callers are (855) 859-2056 and (404) 537-3406, respectively. The conference ID number for the replay is 5178059.

On October 28, 2021 Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise, reported that it will report its third quarter and first nine months of 2021 financial results on Thursday, November 4, 2021 after the close of the U.S. financial markets (Press release, Prothena, OCT 28, 2021, View Source [SID1234592195]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Consistent with past practice, the Company will not be conducting a conference call in conjunction with this financial results release on November 4.

On October 28, 2021 Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (Nasdaq: YMAB) reported that it will report its financial results for the quarter ended September 30, 2021 on Thursday, November 4, 2021, after the close of the U.S. financial markets (Press release, Y-mAbs Therapeutics, OCT 28, 2021, View Source [SID1234592193]). The announcement will be followed by a conference call and webcast with the investment community on Friday, November 5, 2021, at 9 a.m. ET. Participating on the call from Y-mAbs will be Thomas Gad, founder, Chairman and President; Dr. Claus Moller, Chief Executive Officer; and Bo Kruse, Chief Financial Officer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On October 28, 2021 Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), reported that it will release its third quarter 2021 financial results on Wednesday, November 3, 2021 after the markets close (Press release, Lexicon Pharmaceuticals, OCT 28, 2021, View Source [SID1234592186]). Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00 p.m. CT) that day to discuss the financial results and to provide a business update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The dial-in replay will be available for 14 days following the call. An audio webcast will be available online at www.lexpharma.com/events, with a webcast replay accessible for 14 days after the call.

On October 28, 2021 HUYABIO International (HUYABIO), the leader in accelerating global development of China’s pharmaceutical innovations, reported the FDA clearance of HBI-2376 as an Investigational New Drug, or IND, for a Phase 1 study (Press release, HUYA Bioscience, OCT 28, 2021, View Source [SID1234592181]). The authorization to proceed enables the first testing in patients for whom this novel SHP2 inhibitor might show clinical benefit.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased to see that our partner HUYABIO is initiating clinical testing of our SHP2 inhibitor in the US, which will complement Genhouse’s clinical development program in China. We are expecting IND approval in November in China. We believe our SHP2 inhibitor will bring clinical benefit to cancer patients worldwide," said Dr. Kuifeng Wang, CEO of Genhouse.

The HUYABIO-sponsored Phase 1 trial is an open-label dose escalation study using the Company’s SHP2 inhibitor to measure the safety and tolerability in patients with solid tumors harboring KRAS or EGFR mutations. Anti-tumor effects of the monotherapy, determined according to RECIST 1.1, included among the secondary endpoints of the study. Up to 6 sites in the US will be involved in the study that will enroll 42 patients.

Dr. Mireille Gillings, CEO & Executive Chair of HUYABIO said, "We are excited to have FDA clearance to begin clinical testing of HBI-2376 because of the enormous potential of the drug against a number of different tumors. This represents another important milestone for HUYABIO in building a strong oncology pipeline with products that address significant unmet need and provide potential benefit to patients afflicted with debilitating malignancies."

About HBI-2376

HBI-2376 is an oral small molecule inhibitor of SHP2 targeting multiple tumor types whose cellular growth is dependent on the activity of receptor tyrosine kinases in the mitogen-activated protein kinase, or MAPK, pathway. Extensive biochemical characterization has shown that HBI-2376 is a highly potent and selective inhibitor of SHP2 phosphatase with the potential for activity as a single agent or in combination with various other targeted agents, including checkpoint inhibitors.